BDX
Becton, Dickinson and Company
NYSE · USHealthcareMedical - Instruments & Supplies
$154.48-2.33%
Price as of Jul 20, 2026
BDX financials
Becton, Dickinson and Company financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $21.8B | $20.2B | $19.4B | $18.9B |
| Cost of revenue | $11.9B | $11.1B | $11.2B | $10.4B |
| Gross profit | $9.9B | $9.1B | $8.2B | $8.5B |
| Operating expenses | $7.3B | $6.7B | $6.1B | $6.2B |
| Operating income | $2.6B | $2.4B | $2.1B | $2.3B |
| Net income | $1.7B | $1.7B | $1.5B | $1.8B |
| EBITDA | $5.0B | $4.8B | $4.4B | $4.4B |
| Basic EPS | $5.84 | $5.88 | $4.97 | $5.93 |
| Diluted EPS | $5.83 | $5.86 | $4.94 | $5.88 |
| Balance sheet | ||||
| Cash & equivalents | $851.0M | $1.9B | $1.4B | $1.2B |
| Total assets | $55.3B | $57.3B | $52.8B | $52.9B |
| Total liabilities | $29.9B | $31.4B | $27.0B | $27.7B |
| Stockholders’ equity | $25.4B | $25.9B | $25.8B | $25.3B |
| Total debt | $19.2B | $21.6B | $16.8B | $17.0B |
| Net debt | $18.3B | $19.7B | $15.3B | $15.8B |
| Cash flow | ||||
| Operating cash flow | $3.4B | $3.8B | $3.0B | $2.6B |
| Capital expenditure | -$760.0M | -$725.0M | -$874.0M | -$973.0M |
| Free cash flow | $2.7B | $3.1B | $2.1B | $1.7B |
| Dividends paid | -$1.2B | -$1.1B | -$1.1B | -$1.1B |
| Share repurchases | -$1.0B | -$500.0M | $0.00 | -$500.0M |